Why the study?
Does NOAC prevent stroke recurrence in a patient with recurrent posterior circulation strokes of undetermined etiology despite antiplatelet therapy?
Does NOAC prevent stroke recurrence in a patient with recurrent posterior circulation strokes of undetermined etiology despite antiplatelet therapy?
NOAC therapy may be effective in preventing recurrent posterior circulation strokes of undetermined etiology when antiplatelet therapy fails.
Answers are grounded in this paper and cite their sources.
May support NOAC consideration after antiplatelet failure in undetermined posterior strokes; hypothesis-generating from one case and requires trials.
Current stroke guidelines recommend the administration of non-vitamin-K-antagonist oral anticoagulant (NOAC) for the prevention of cardioembolic stroke induced by nonvalvular atrial fibrillation. We report a patient who suffered from recurrent posterior circulation strokes-occurring eight times in 4 months-even under adequate antiplatelet medication. Changing the medication from antiplatelet agents to NOAC stopped the stroke recurrence. We suggest that NOAC has a role in the prevention of recurrent stroke of undetermined etiology in the posterior circulation.
No takes yet. Share an insight, caveat, or question.
Han et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: